Trade Names:Hytrin- Capsules 1 mg- Capsules 2 mg- Capsules 5 mg- Capsules 10 mgApo-Terazosin (Canada)Novo-Terazosin (Canada)PMS-Terazosin (Canada)ratio-Terazosin (Canada)
Selectively blocks postsynaptic alpha 1 -adrenergic receptors, resulting in dilation of arterials and veins.
Oral terazosin is completely absorbed. Food delayed the time to peak concentration by 1 h. T max occurs 1 h after dosing.
Terazosin is 90% to 94% bound to plasma proteins.
Terazosin undergoes minimal first-pass metabolism.
Terazosin t ½ is approximately 12 h. Approximately 40% of an orally administered dose is excreted in urine and approximately 60% is excreted in feces.
After oral administration, plasma Cl was decreased 31.7% in patients older than 70 yr of age vs patients 20 to 39 yr of age.
Management of hypertension and symptomatic benign prostatic hyperplasia (BPH).
Hypersensitivity to doxazosin or prazosin.
PO Initial: 1 mg at bedtime. (Do not exceed this as initial dose to avoid severe hypotensive effects; reinstitute at this dose if drug is discontinued for several days). Maintenance: 1 to 5 mg every day; may consider twice daily dosing (max, 20 mg/day).BPHAdults
1 mg at bedtime. (Do not exceed this as initial dose); increase dose in step-wise fashion.Usual maintenance
10 mg every day for minimum of 4 to 6 wk (max, 20 mg/day).
Store in tight container in cool location.
None well documented.
None well documented.
Palpitations; orthostatic hypotension; hypotension; tachycardia; arrhythmias; vasodilation.
Dizziness; nervousness; paresthesia; somnolence; anxiety; headache; insomnia; weakness; drowsiness.
Pruritus; rash; sweating.
Blurred or abnormal vision; conjunctivitis; tinnitus; nasal congestion; sinusitis; epistaxis; pharyngitis.
Nausea; vomiting; dry mouth; diarrhea; constipation; abdominal discomfort or pain; flatulence.
Impotence; urinary frequency; UTI.
Dyspnea; bronchitis; bronchospasm; flu symptoms; increased cough.
Shoulder, neck, back, or extremity pain; arthralgia; edema; fever; weight gain.
Category C .
Safety and efficacy not established.
Long-term effects on incidence of surgery, acute urinary obstruction, or other complications of BPH have not been determined.
May cause marked hypotension (especially orthostatic) and syncope at 15 to 90 min after first few doses, after reintroduction, with rapid increase in dosing, or after addition of another antihypertensive; to avoid, initiate dosing with low dose and gradually increase after 2 wk; monitor patients carefully.
Small decreases in hematocrit, hemoglobin, WBCs, total protein, and albumin may occur, possibly because of hemodilution.
Copyright © 2009 Wolters Kluwer Health.